Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose reduction vs maintenance antipsychotics stratified by psychotic phenotype in SSD
2023-509558-80-00Phase 3Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- May 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of risperidone, flupentixol, levomepromazine, Aminazin, loxapine and 9 more in schizophrenia, schizophreniform disorder, schizoaffective disorder and 1 more (2 arms), sponsored by Strasbourg University Hospital. Planned start May 2025; status: authorised.
02
Drugs
risperidoneflupentixollevomepromazineAminazinloxapine
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorderbrief psychotic disorder (BPD)
Beyond the preview
Go deeper on 2023-509558-80-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509558-80-00.